Columbia Laboratories (CBRX) 7.36 $CBRX Viramal Appoints

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Columbia Laboratories (CBRX) 7.36 $CBRX

Viramal Appoints Women's Healthcare Expert, William Bologna, as Chairman of the Board of Directors
BusinessWire - Tue Feb 02, 7:30AM CST
Viramal, ("the Company" , an emerging specialty pharmaceutical company developing therapeutics that improve the quality of women's health, today announced the appointment of William Bologna as Chairman of the Board of Directors, effective immediately. Mr. Bologna is also the Company's chief scientist.
CBRX: 7.36 (+0.45)

Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)
PR Newswire - Mon Apr 13, 6:00AM CDT
Effective this morning, Columbia Laboratories, Inc. is now Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company" , and its Nottingham, UK based subsidiary Molecular Profiles, Ltd., is now Juniper Pharma Services. The Company's common stock will begin trading today under the symbol JNP on the Nasdaq Stock Exchange.
JNP: 5.51 (-0.01), CBRX: 7.36 (+0.45)

Columbia Laboratories announces new brand name & new trading symbol
M2 - Fri Apr 03, 3:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Thursday that it will adopt its new corporate brand name of Juniper Pharmaceuticals with effect from 10 April 2015.
CBRX: 7.36 (+0.45)

Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.
PR Newswire - Thu Apr 02, 6:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) (the "Company" , today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol -- "JNP" -- on Monday, April 13, 2015. The Company will also unveil its new logo and launch its new website, www.juniperpharma.com, on April 13, 2015.
CBRX: 7.36 (+0.45)

Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (8) - - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 20.23 (-0.47), ACT: 298.98 (-2.94), AUXL: 36.47 (-0.06), LLY: 77.23 (-0.52), ABBV: 64.03 (-0.07), CBRX: 7.36 (+0.45), ATRS: 1.21 (-0.01)

Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology
PR Newswire - Mon Mar 30, 7:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring ("IVR" technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring.
CBRX: 7.36 (+0.45)

Columbia Laboratories Shares Up 5.7% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Mon Mar 23, 11:28AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 1 month, Columbia Laboratories has returned 5.68% as of today's recent price of $6.36.
CBRX: 7.36 (+0.45)

Columbia Laboratories posts lower net income of USD3.4m for 2014
M2 - Thu Mar 19, 6:35AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Wednesday that its net income was USD3.4m (USD0.27 per diluted share) for the 12-month period ended 31 December 2014.
CBRX: 7.36 (+0.45)

Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 18, 1:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
VUZI: 8.92 (+0.07), ADXS: 11.78 (+0.25), ASPS: 32.88 (+0.30), VTAE: 6.84 (-0.07), HCCI: 13.35 (-0.46), AIRT: 20.11 (-1.84), CBRX: 7.36 (+0.45), TESO: 6.86 (+0.05), BOOM: 10.39 (-0.61), AVID: 9.04 (+0.05), ALOT: 14.93 (+0.20), RTRX: 16.35 (+0.33), TUES: 6.71 (+0.04), FPRX: 44.74 (+0.76), KPTI: 11.10 (+1.15)

Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results
PR Newswire - Wed Mar 18, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or the "Company" , today announced financial results for the three- and twelve-month periods ended December 31, 2014.
CBRX: 7.36 (+0.45)

Uptrend Call Working As Columbia Laboratories Stock Rises 34.8% (CBRX)
Comtex SmarTrend(R) - Mon Mar 16, 11:27AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 3 weeks, Columbia Laboratories has returned 34.83% as of today's recent price of $8.11.
CBRX: 7.36 (+0.45)

Federal Appeals Court Affirms Dismissal of Class Action Lawsuit
PR Newswire - Thu Mar 12, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on the development of pharmaceuticals for women's health, announced today that the United States Court of Appeals for the Third Circuit affirmed the prior decision of the United States District Court for the District of New Jersey dismissing the securities class action lawsuit, entitled In re Columbia Laboratories, Inc., Securities Litigation, (D.C. No. 2-12-cv-00614) filed against Columbia, Watson Pharmaceuticals, Inc ("Watson" , and various Columbia and Watson executives.
CBRX: 7.36 (+0.45)

Columbia Laboratories to Discuss Fourth Quarter and Full Year 2014 Financial Results on March 18th Conference Call
PR Newswire - Tue Mar 10, 3:44PM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 18, 2015, to discuss financial results for the fourth quarter and full year ended December 31, 2014. The call details are as follows:
CBRX: 7.36 (+0.45)

Uptrend Call Working As Columbia Laboratories Stock Rises 23.7% (CBRX)
Comtex SmarTrend(R) - Mon Mar 09, 9:57AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on February 20th, 2015 at $6.02. In approximately 2 weeks, Columbia Laboratories has returned 23.69% as of today's recent price of $7.44.
CBRX: 7.36 (+0.45)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 28

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 25

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 64

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 192

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 31

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 328

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 13

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading

Top 5 Most Recently Viewed Articles

GM Partners with Barclays to Enhance Credit Card Offerings

Updated Category News Views 71

General Motors and Barclays Sign a Strategic Partnership General Motors (NYSE: GM) and Barclays have recently announced a significant long-term partnership that focuses on credit card services. This strategic agreement reflects both companies' commitment to enhancing customer experience and providing innovative financial solutions. Benefits of the New Credit Card...

Continue Reading
Enbridge Inc. Declares 3% Increase in Quarterly Dividend

Updated Category News Views 126

Enbridge Inc. Increases Quarterly Dividend by 3% Enbridge Inc. (TSX: ENB) has made a significant announcement regarding its quarterly dividend. The company declared a quarterly dividend of $0.9425 per common share, signaling a 3% increase from previous rates. This notable hike reflects Enbridge's commitment to shareholder value and marks the thirtieth consecutive year of...

Continue Reading
Jefferies Advises Caution on Biotech-Related CRO Investments

Updated Category News Views 545

CROs Confront Challenges as Biotech Market Slows In a recent analysis, Jefferies is advising investors to rethink their investments in contract research organizations (CROs), particularly those focused on biotech and early-stage research. This caution comes as the demand in the biotech sector has noticeably declined. Financial Struggles Affects Companies Jefferies has...

Continue Reading
Remarkable Cost Savings with QUELIMMUNE for Pediatric AKI

Updated Category News Views 137

Significant Economic Impact of QUELIMMUNE Therapy SeaStar Medical Holding Corporation (Nasdaq: ICU), a pioneering healthcare company, has recently published a health economic analysis that underscores the substantial financial benefits of its QUELIMMUNE therapy for pediatric patients suffering from Acute Kidney Injury (AKI). The analysis highlights an estimated average...

Continue Reading
SKF Invites Fans to Revitalize Tattoos with Brand Update

Updated Category News Views 228

SKF Invites Fans to Revitalize Tattoos with Brand Update SKF has taken an impactful step to modernize its brand identity, showcasing a fresh and dynamic look aimed at connecting with its audience more effectively. This update marks the company's first significant change to its logo since its inception in 1908, highlighting the dedication to innovation while respecting its...

Continue Reading